Alkem Laboratories Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
5066.80 +89.45 (1.80%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4999.6
Today’s High
5086.2
52 Week Low
3440.05
52 Week High
5581.2
5063.55 +82.20 (1.65%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4990.6
Today’s High
5085
52 Week Low
3442
52 Week High
5578.8
Key Metrics
- Market Cap (In Cr) 59559.51
- Beta 0.61
- Div. Yield (%) 0.8
- P/B 5.77
- TTM P/E 32.9
- Peg Ratio 1.8
- Sector P/E 30.88
- D/E 0.14
- Open Price 4999.6
- Prev Close 4977.35
Alkem Laboratories Analysis
Price Analysis
-
1 Week1.17%
-
3 Months2.37%
-
6 Month-5.47%
-
YTD-4.25%
-
1 Year41.83%
Risk Meter
- 29% Low risk
- 29% Moderate risk
- 29% Balanced Risk
- 29% High risk
- 29% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 4
- 4
- 4
- 6
- Hold
- 6
- 6
- 6
- 6
- Sell
- 3
- 3
- 3
- 3
- Strong Sell
- 3
- 3
- 3
- 3
- Total
- 18
- 18
- 18
- 20
Alkem Laboratories News
Alkem Laboratories share price declines 9% post Q4 results: Buy, Sell or Hold?
3 min read . 30 May 2024Stocks to watch: Tata Steel, Cummins, Lemon Tree Hotels, Heritage Foods, SJVN
6 min read . 30 May 2024Alkem posts a three-fold increase in Q4 net profit to ₹293.56 crore
2 min read . 29 May 2024Alkem Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 12667.58
- Selling/ General/ Admin Expenses Total
- 2201.01
- Depreciation/ Amortization
- 299.3
- Other Operating Expenses Total
- 3283.5
- Total Operating Expense
- 10721.39
- Operating Income
- 1946.19
- Net Income Before Taxes
- 2023.13
- Net Income
- 1795.77
- Diluted Normalized EPS
- 150.19
- Period
- 2024
- Total Assets
- 15574.9
- Total Liabilities
- 5262.84
- Total Equity
- 10312.06
- Tangible Book Valueper Share Common Eq
- 822.9
- Period
- 2024
- Cashfrom Operating Activities
- 1948.07
- Cashfrom Investing Activities
- -1008.5
- Cashfrom Financing Activities
- -1145.01
- Net Changein Cash
- -207.49
- Period
- 2023
- Total Revenue
- 11599.26
- Selling/ General/ Admin Expenses Total
- 4877.77
- Depreciation/ Amortization
- 310.42
- Other Operating Expenses Total
- 96.33
- Total Operating Expense
- 10320.11
- Operating Income
- 1279.15
- Net Income Before Taxes
- 1304.77
- Net Income
- 984.17
- Diluted Normalized EPS
- 89.9
- Period
- 2023
- Total Assets
- 13756.63
- Total Liabilities
- 4711.34
- Total Equity
- 9045.29
- Tangible Book Valueper Share Common Eq
- 715.32
- Period
- 2023
- Cashfrom Operating Activities
- 1682.5
- Cashfrom Investing Activities
- 112.84
- Cashfrom Financing Activities
- -1760.82
- Net Changein Cash
- 41.62
- Period
- 2022
- Total Revenue
- 10634.19
- Selling/ General/ Admin Expenses Total
- 4240.27
- Depreciation/ Amortization
- 303.96
- Other Operating Expenses Total
- 53.51
- Total Operating Expense
- 8862.68
- Operating Income
- 1771.51
- Net Income Before Taxes
- 1844.28
- Net Income
- 1645.62
- Diluted Normalized EPS
- 137.57
- Period
- 2022
- Total Assets
- 14069.19
- Total Liabilities
- 5431.29
- Total Equity
- 8637.9
- Tangible Book Valueper Share Common Eq
- 682.69
- Period
- 2022
- Cashfrom Operating Activities
- 1111.02
- Cashfrom Investing Activities
- -1435.13
- Cashfrom Financing Activities
- 379.57
- Net Changein Cash
- 57.96
- Period
- 2021
- Total Revenue
- 8865.01
- Selling/ General/ Admin Expenses Total
- 3277.01
- Depreciation/ Amortization
- 274.58
- Other Operating Expenses Total
- 54.83
- Total Operating Expense
- 7195.53
- Operating Income
- 1669.48
- Net Income Before Taxes
- 1842.1
- Net Income
- 1585.02
- Diluted Normalized EPS
- 129.72
- Period
- 2021
- Total Assets
- 11519.26
- Total Liabilities
- 4142.53
- Total Equity
- 7376.73
- Tangible Book Valueper Share Common Eq
- 576.83
- Period
- 2021
- Cashfrom Operating Activities
- 1264.9
- Cashfrom Investing Activities
- -998.54
- Cashfrom Financing Activities
- -271.75
- Net Changein Cash
- -1.72
- Period
- 2020
- Total Revenue
- 8344.36
- Selling/ General/ Admin Expenses Total
- 3310.36
- Depreciation/ Amortization
- 252.76
- Other Operating Expenses Total
- 71.43
- Total Operating Expense
- 7057.36
- Operating Income
- 1287
- Net Income Before Taxes
- 1259.79
- Net Income
- 1127.07
- Diluted Normalized EPS
- 94.42
- Period
- 2020
- Total Assets
- 9945.54
- Total Liabilities
- 3784.87
- Total Equity
- 6160.67
- Tangible Book Valueper Share Common Eq
- 473.7
- Period
- 2020
- Cashfrom Operating Activities
- 585.08
- Cashfrom Investing Activities
- -741.35
- Cashfrom Financing Activities
- 79.15
- Net Changein Cash
- -73.11
- Period
- 2019
- Total Revenue
- 7357.19
- Selling/ General/ Admin Expenses Total
- 3082.65
- Depreciation/ Amortization
- 193.18
- Other Operating Expenses Total
- 58.7
- Total Operating Expense
- 6396.56
- Operating Income
- 960.63
- Net Income Before Taxes
- 954.66
- Net Income
- 760.51
- Diluted Normalized EPS
- 63.98
- Period
- 2019
- Total Assets
- 8208.19
- Total Liabilities
- 2768.85
- Total Equity
- 5439.34
- Tangible Book Valueper Share Common Eq
- 419.4
- Period
- 2019
- Cashfrom Operating Activities
- 779.65
- Cashfrom Investing Activities
- -316.39
- Cashfrom Financing Activities
- -378.94
- Net Changein Cash
- 82.34
- Period
- 2018
- Total Revenue
- 6431.18
- Selling/ General/ Admin Expenses Total
- 2628.97
- Depreciation/ Amortization
- 143.03
- Other Operating Expenses Total
- 143.33
- Total Operating Expense
- 5539.17
- Operating Income
- 892.01
- Net Income Before Taxes
- 925.98
- Net Income
- 630.94
- Diluted Normalized EPS
- 52.74
- Period
- 2018
- Total Assets
- 7665.63
- Total Liabilities
- 2801.86
- Total Equity
- 4863.77
- Tangible Book Valueper Share Common Eq
- 372.47
- Period
- 2018
- Cashfrom Operating Activities
- 266.04
- Cashfrom Investing Activities
- -357.23
- Cashfrom Financing Activities
- 84.56
- Net Changein Cash
- 0.08
- Period
- 2024-03-31
- Total Revenue
- 2935.82
- Selling/ General/ Admin Expenses Total
- 505.83
- Depreciation/ Amortization
- 83.43
- Other Operating Expenses Total
- 920.61
- Total Operating Expense
- 2617.27
- Operating Income
- 318.55
- Net Income Before Taxes
- 367.34
- Net Income
- 293.56
- Diluted Normalized EPS
- 24.55
- Period
- 2024-03-31
- Total Assets
- 15574.9
- Total Liabilities
- 5262.84
- Total Equity
- 10312.06
- Tangible Book Valueper Share Common Eq
- 822.9
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1948.07
- Cashfrom Investing Activities
- -1008.5
- Cashfrom Financing Activities
- -1145.01
- Net Changein Cash
- -207.49
- Period
- 2023-12-31
- Total Revenue
- 3323.87
- Selling/ General/ Admin Expenses Total
- 572.15
- Depreciation/ Amortization
- 69.56
- Other Operating Expenses Total
- 739.59
- Total Operating Expense
- 2685.84
- Operating Income
- 638.03
- Net Income Before Taxes
- 654.9
- Net Income
- 594.96
- Diluted Normalized EPS
- 49.76
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 3440.17
- Selling/ General/ Admin Expenses Total
- 555.38
- Depreciation/ Amortization
- 73.9
- Other Operating Expenses Total
- 810.99
- Total Operating Expense
- 2767.34
- Operating Income
- 672.83
- Net Income Before Taxes
- 648.04
- Net Income
- 620.52
- Diluted Normalized EPS
- 51.9
- Period
- 2023-09-30
- Total Assets
- 14925.68
- Total Liabilities
- 5083.19
- Total Equity
- 9842.49
- Tangible Book Valueper Share Common Eq
- 781.26
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 934.92
- Cashfrom Investing Activities
- -625.2
- Cashfrom Financing Activities
- -261.72
- Net Changein Cash
- 47.02
- Period
- 2023-06-30
- Total Revenue
- 2967.72
- Selling/ General/ Admin Expenses Total
- 567.65
- Depreciation/ Amortization
- 72.41
- Other Operating Expenses Total
- 812.31
- Total Operating Expense
- 2650.94
- Operating Income
- 316.78
- Net Income Before Taxes
- 352.85
- Net Income
- 286.73
- Diluted Normalized EPS
- 23.98
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 2902.6
- Selling/ General/ Admin Expenses Total
- 502.98
- Depreciation/ Amortization
- 78.32
- Other Operating Expenses Total
- 790.85
- Total Operating Expense
- 2627.67
- Operating Income
- 274.93
- Net Income Before Taxes
- 211.66
- Net Income
- 70.98
- Diluted Normalized EPS
- 5.94
- Period
- 2023-03-31
- Total Assets
- 13756.63
- Total Liabilities
- 4711.34
- Total Equity
- 9045.29
- Tangible Book Valueper Share Common Eq
- 715.32
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 1682.5
- Cashfrom Investing Activities
- 112.84
- Cashfrom Financing Activities
- -1760.82
- Net Changein Cash
- 41.62
- Period
- 2022-12-31
- Total Revenue
- 3040.91
- Selling/ General/ Admin Expenses Total
- 525.37
- Depreciation/ Amortization
- 78.44
- Other Operating Expenses Total
- 667.55
- Total Operating Expense
- 2520.3
- Operating Income
- 520.61
- Net Income Before Taxes
- 538.89
- Net Income
- 454.71
- Diluted Normalized EPS
- 38.03
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Alkem Laboratories Technical
Moving Average
SMA
- 5 Day4977.98
- 10 Day4985.71
- 20 Day5043.54
- 50 Day5039.91
- 100 Day5051.79
- 300 Day4699.57
Alkem Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Torrent Pharmaceuticals
- 2880
- 8.95
- 0.31
- 2977.1
- 1771.35
- 97476.48
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Alkem Laboratories
- 5066.8
- 89.45
- 1.8
- 5581.2
- 3440.05
- 60573.59
- Abbott India
- 27820.25
- -65.3
- -0.23
- 29628.15
- 21907.45
- 59116.08
- Glaxosmithkline Pharmaceuticals
- 2542
- -47.05
- -1.82
- 2759
- 1376.5
- 43063.01
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Torrent Pharmaceuticals
- 59.9
- 14.01
- 20.64
- 13.18
- Lupin
- 38.94
- 5.2
- 2.51
- 2.04
- Alkem Laboratories
- 33.1
- 5.76
- 18.26
- 13.94
- Abbott India
- 48.82
- 15.85
- 30.46
- 17.26
- Glaxosmithkline Pharmaceuticals
- 63.64
- 24.81
- 20.45
- 12.25
Alkem Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results & Interim Dividend
- 07-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results & Interim Dividend
- 11-Nov-22
- Quarterly Results
- 05-Aug-22
- Quarterly Results
- 13-May-22
- Audited Results & Final Dividend
- 04-Feb-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 08-Jan-24
- 07-Dec-23
- POM
- 09-Oct-23
- 07-Sept-23
- POM
- 25-Aug-22
- 13-May-22
- AGM
- 14-Feb-22
- 11-Jan-22
- POM
- 27-Aug-21
- 25-May-21
- AGM
- 26-Mar-21
- 22-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-May-24
- 10-Aug-24
- -
- 5
- 01-Feb-24
- 17-Feb-24
- 16-Feb-24
- 35
- 19-May-23
- 10-Aug-23
- 10-Aug-23
- 10
- 25-Jan-23
- 18-Feb-23
- 17-Feb-23
- 25
- 24-Jan-23
- 18-Feb-23
- 17-Feb-23
- 15
- 13-May-22
- 10-Aug-22
- 08-Aug-22
- 4
- 24-Jan-22
- 12-Feb-22
- 10-Feb-22
- 30
- 25-May-21
- 10-Aug-21
- 09-Aug-21
- 5
- 27-Jan-21
- 13-Feb-21
- 11-Feb-21
- 25